Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, has received approval from the U.S. Food and Drug Administration (FDA) for a revised label of UNLOXCYT™ (cosibelimab-ipdl), following strong long-term clinical outcomes from its pivotal CK-301-101 study. The updated label positions the therapy as a frontline option for patients with advanced cutaneous squamous cell carcinoma (aCSCC), including both metastatic (mCSCC) and locally advanced (laCSCC) cases that are not suitable for surgery or radiation.

Strong Long-Term Efficacy Drives Label Expansion

The updated clinical dataset—now expanded to 109 patients—reinforces the therapy’s durable performance. More than half of the enrolled patients achieved an objective response, with meaningful improvement across disease categories:

• Complete Response: 13% in mCSCC; 26% in laCSCC
• Partial Response: 37% in mCSCC; 29% in laCSCC
• Median Duration of Response (mDOR): Not yet reached in either group
• Durable Benefit: 67% of mCSCC and 88% of laCSCC responders maintained improvement for at least 12 months
• Median Time to Response: 1.9 months (mCSCC) and 3.6 months (laCSCC)

The findings highlight sustained clinical benefit and long-lasting disease control—critical in a disease where treatment options remain limited.

Consistent Safety with No New Adverse Concerns

Sun Pharma noted that the safety profile of UNLOXCYT remains consistent with earlier findings. Reported immune-mediated adverse effects—such as fatigue, musculoskeletal pain, rash, and gastrointestinal symptoms—were manageable and aligned with expectations for checkpoint inhibitors. Importantly, no treatment-related fatalities were recorded during the study.

Leadership and Expert Commentary

Richard Ascroft, CEO of Sun Pharma North America, emphasised that the updated data reflects an “evolution in checkpoint inhibition,” reinforcing UNLOXCYT’s growing relevance in the aCSCC therapeutic landscape.

Dr. Emily Ruiz of Harvard Medical School, a lead investigator in the long-term study, highlighted the significance of durable responses paired with tolerability—particularly for older patients or those with multiple comorbidities. She noted that these attributes address a long-standing unmet need in a vulnerable patient population.

Commercial Rollout Planned for Early 2026

With the expanded label now approved, Sun Pharma plans a market launch in early 2026, further integrating UNLOXCYT into its expanding oncology portfolio. The therapy was initially approved in 2024, and the strengthened dataset is expected to bolster clinician confidence and adoption.

Also read: Zydus Partners with RK Pharma for US Commercialisation of Novel 505(b)(2) Oncology Injectable

Addressing a Major Public Health Challenge

Cutaneous squamous cell carcinoma is among the most common skin cancers worldwide. While early stages are treatable, an estimated 40,000 U.S. patients each year progress to advanced disease, resulting in nearly 15,000 deaths, underscoring the urgent need for more effective therapies. The updated label for UNLOXCYT marks a significant step toward improving outcomes for this high-risk group.

As Sun Pharma continues to deepen its foothold in the global oncology market, the UNLOXCYT approval highlights India’s growing capability in developing advanced, globally relevant cancer therapeutics.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!